Differences in Age at Onset of Symptoms, and Effects of Genetic Variants, in Patients With Early vs Late-Onset Idiopathic Chronic Pancreatitis in a North American Cohort.


Journal

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
ISSN: 1542-7714
Titre abrégé: Clin Gastroenterol Hepatol
Pays: United States
ID NLM: 101160775

Informations de publication

Date de publication:
02 2021
Historique:
received: 10 02 2020
revised: 13 03 2020
accepted: 22 03 2020
pubmed: 3 4 2020
medline: 19 8 2021
entrez: 3 4 2020
Statut: ppublish

Résumé

Idiopathic chronic pancreatitis (ICP) is the second most common subtype of CP. In 1994, researchers reported the bimodal age at onset of ICP symptoms: early onset ICP (EO-ICP; median age, 19.2 y) and late-onset ICP (LO-ICP; median age, 56.2 y). Ages of onset and clinical features of ICP differed from those of alcohol-related CP (ACP). However, variants in PRSS1 had not yet been associated with ICP. We reexamined ages of onset of ICP in a large, North American cohort of patients, and investigated the effects of genetic factors and alcohol use in patients with EO-ICP, LO-ICP, and ACP. We performed a cross-sectional analysis of patients with CP of European ancestry enrolled in the North American Pancreatitis Study 2, a prospective study of 1195 patients with CP from 26 centers in the United States from August 2000 through December 2014. We compared age at onset of symptoms for 130 patients with CP who were lifetime abstainers from alcohol (61 patients with early onset and 69 patients with late onset), 308 light to moderate alcohol drinkers with CP, and 225 patients with ACP and heavy to very heavy alcohol use. DNA from available patients was analyzed for variants associated with CP in SPINK1, CFTR, and CTRC. The Kruskal-Wallis test was used to compare continuous variables across groups and based on genetic variants. Median ages at onset of symptoms were 20 years for patients with EO-ICP and no alcohol use, 58 years for patients with LO-ICP and no alcohol use, 47 years for light to moderate alcohol drinkers with CP, and 44 years for patients with ACP. A higher proportion of patients with EO-ICP had constant pain (65%) than patients with LO-ICP (31%) (P = .04). A higher proportion of patients with ACP had pseudocysts (43%) than patients with EO-ICP (11%) (P = .001). A higher proportion of patients with EO-ICP had pathogenic variants in SPINK1, CFTR, or CTRC (49%) than patients with LO-ICP (23%), light to moderate alcohol drinking with CP (26%), or ACP (23%) (P = .001). Among patients with variants in SPINK1, those with EO-ICP had onset of symptoms at a median age of 12 years, and light to moderate alcohol drinkers with CP had an age at onset of 24 years. Among patients with variants in CFTR, light to moderate alcohol drinkers had an age at onset of symptoms of 41 years, but this variant did not affect age at onset of EO-ICP or ACP. We confirmed previously reported ages at onset of symptoms for EO-ICP and LO-ICP in a North American cohort. We found differences in clinical features among patients with EO-ICP, LO-ICP, and ACP. Almost half of patients with EO-ICP have genetic variants associated with CP, compared with approximately one quarter of patients with LO-CP or ACP. Genetic variants affect ages at onset of symptoms in some groups.

Sections du résumé

BACKGROUND & AIMS
Idiopathic chronic pancreatitis (ICP) is the second most common subtype of CP. In 1994, researchers reported the bimodal age at onset of ICP symptoms: early onset ICP (EO-ICP; median age, 19.2 y) and late-onset ICP (LO-ICP; median age, 56.2 y). Ages of onset and clinical features of ICP differed from those of alcohol-related CP (ACP). However, variants in PRSS1 had not yet been associated with ICP. We reexamined ages of onset of ICP in a large, North American cohort of patients, and investigated the effects of genetic factors and alcohol use in patients with EO-ICP, LO-ICP, and ACP.
METHODS
We performed a cross-sectional analysis of patients with CP of European ancestry enrolled in the North American Pancreatitis Study 2, a prospective study of 1195 patients with CP from 26 centers in the United States from August 2000 through December 2014. We compared age at onset of symptoms for 130 patients with CP who were lifetime abstainers from alcohol (61 patients with early onset and 69 patients with late onset), 308 light to moderate alcohol drinkers with CP, and 225 patients with ACP and heavy to very heavy alcohol use. DNA from available patients was analyzed for variants associated with CP in SPINK1, CFTR, and CTRC. The Kruskal-Wallis test was used to compare continuous variables across groups and based on genetic variants.
RESULTS
Median ages at onset of symptoms were 20 years for patients with EO-ICP and no alcohol use, 58 years for patients with LO-ICP and no alcohol use, 47 years for light to moderate alcohol drinkers with CP, and 44 years for patients with ACP. A higher proportion of patients with EO-ICP had constant pain (65%) than patients with LO-ICP (31%) (P = .04). A higher proportion of patients with ACP had pseudocysts (43%) than patients with EO-ICP (11%) (P = .001). A higher proportion of patients with EO-ICP had pathogenic variants in SPINK1, CFTR, or CTRC (49%) than patients with LO-ICP (23%), light to moderate alcohol drinking with CP (26%), or ACP (23%) (P = .001). Among patients with variants in SPINK1, those with EO-ICP had onset of symptoms at a median age of 12 years, and light to moderate alcohol drinkers with CP had an age at onset of 24 years. Among patients with variants in CFTR, light to moderate alcohol drinkers had an age at onset of symptoms of 41 years, but this variant did not affect age at onset of EO-ICP or ACP.
CONCLUSIONS
We confirmed previously reported ages at onset of symptoms for EO-ICP and LO-ICP in a North American cohort. We found differences in clinical features among patients with EO-ICP, LO-ICP, and ACP. Almost half of patients with EO-ICP have genetic variants associated with CP, compared with approximately one quarter of patients with LO-CP or ACP. Genetic variants affect ages at onset of symptoms in some groups.

Identifiants

pubmed: 32240833
pii: S1542-3565(20)30424-9
doi: 10.1016/j.cgh.2020.03.047
pmc: PMC7529676
mid: NIHMS1580554
pii:
doi:

Substances chimiques

SPINK1 protein, human 0
Trypsin Inhibitor, Kazal Pancreatic 50936-63-5
Trypsin EC 3.4.21.4

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

349-357

Subventions

Organisme : NIDDK NIH HHS
ID : R56 DK061451
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000005
Pays : United States
Organisme : NCRR NIH HHS
ID : UL1 RR024153
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK108306
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK077906
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK108320
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK061451
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021. Published by Elsevier Inc.

Références

Nat Genet. 2012 Dec;44(12):1349-54
pubmed: 23143602
N Engl J Med. 1998 Sep 3;339(10):653-8
pubmed: 9725922
Clin Gastroenterol Hepatol. 2015 Mar;13(3):552-60; quiz e28-9
pubmed: 25424572
Mayo Clin Proc. 2001 Mar;76(3):242-51
pubmed: 11243270
Nat Genet. 2000 Jun;25(2):213-6
pubmed: 10835640
PLoS Genet. 2014 Jul 17;10(7):e1004376
pubmed: 25033378
Pancreas. 2011 Apr;40(3):352-8
pubmed: 21412117
Am J Gastroenterol. 2016 Oct;111(10):1488-1496
pubmed: 27527745
Pancreatology. 2008;8(4-5):520-31
pubmed: 18765957
N Engl J Med. 2001 Mar 8;344(10):732-8
pubmed: 11236777
Clin Gastroenterol Hepatol. 2016 May;14(5):738-46
pubmed: 26772149
Gastroenterology. 1994 Nov;107(5):1481-7
pubmed: 7926511
Digestion. 1973;9(5):447-53
pubmed: 4784706
Arch Intern Med. 2009 Jun 8;169(11):1035-45
pubmed: 19506173
Ann Intern Med. 1971 Feb;74(2):264-77
pubmed: 4926436
Therap Adv Gastroenterol. 2017 Mar;10(3):323-336
pubmed: 28246549
Nat Genet. 1996 Oct;14(2):141-5
pubmed: 8841182
Pancreatology. 2018 May 19;18(5):528-535
pubmed: 29859674
Gastroenterology. 2011 Jan;140(1):162-71
pubmed: 20977904
Nat Genet. 2008 Jan;40(1):78-82
pubmed: 18059268
Clin Transl Gastroenterol. 2015 Jan 08;6:e68
pubmed: 25569187
Gastroenterology. 1984 May;86(5 Pt 1):820-8
pubmed: 6706066
Arch Intern Med. 2009 Mar 23;169(6):603-9
pubmed: 19307524
Digestion. 1979;19(2):110-25
pubmed: 478188

Auteurs

Michele D Lewis (MD)

Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida. Electronic address: Lewis.michele@mayo.edu.

Jyothsna Talluri (J)

Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.

C Mel Wilcox (CM)

Division of Gastroenterology, University of Alabama at Birmingham, Birmingham, Alabama.

Judah N Abberbock (JN)

Division of Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania.

Gong Tang (G)

Division of Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania.

Darwin L Conwell (DL)

Division of Gastroenterology, Brigham and Women's Hospital, Boston, Massachusetts.

Peter A Banks (PA)

Division of Gastroenterology, Brigham and Women's Hospital, Boston, Massachusetts.

Gregory A Cote (GA)

Division of Gastroenterology, Indiana University School of Medicine, Indianapolis, Indiana.

Stuart Sherman (S)

Division of Gastroenterology, Indiana University School of Medicine, Indianapolis, Indiana.

Samer Alkaade (S)

Division of Gastroenterology, Saint Louis University School of Medicine, St. Louis, Missouri.

Timothy B Gardner (TB)

Division of Gastroenterology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.

Michelle A Anderson (MA)

Division of Gastroenterology, University of Michigan School of Medicine, Ann Arbor, Michigan.

Bimaljit S Sandhu (BS)

Division of Gastroenterology, Virginia Commonwealth University School of Medicine, Richmond, Virginia.

Thiruvengadam Muniraj (T)

Division of Gastroenterology, Griffin Hospital, Derby, Connecticut.

Chris E Forsmark (CE)

Division of Gastroenterology, University of Florida College of Medicine, Gainesville, Florida.

Nalini Guda (N)

GI Associates, Milwaukee, Wisconsin.

Andres Gelrud (A)

Division of Gastroenterology, University of Chicago School of Medicine, Chicago, Illinois.

Joseph Romagnuolo (J)

Division of Gastroenterology, Medical University of South Carolina, Charleston, South Carolina.

Randall Brand (R)

Division of Gastroenterology, University of Pittsburgh, Pittsburgh, Pennsylvania.

Jessica LaRusch (J)

Division of Gastroenterology, University of Pittsburgh, Pittsburgh, Pennsylvania.

Stephen T Amann (ST)

Digestive Health Specialists, Tupelo, Mississippi.

Adam Slivka (A)

Division of Gastroenterology, University of Pittsburgh, Pittsburgh, Pennsylvania.

David C Whitcomb (DC)

Division of Gastroenterology, University of Pittsburgh, Pittsburgh, Pennsylvania.

Dhiraj Yadav (D)

Division of Gastroenterology, University of Pittsburgh, Pittsburgh, Pennsylvania.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH